Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H13ClFN3 |
Molecular Weight | 325.767 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12
InChI
InChIKey=DDLIGBOFAVUZHB-UHFFFAOYSA-N
InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
Molecular Formula | C18H13ClFN3 |
Molecular Weight | 325.767 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Midazolam, previously marketed under the trade name Versed, is a medication used for anesthesia, procedural sedation, trouble sleeping, and severe agitation. Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the γ-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.
Data from published reports of studies in pediatric patients clearly demonstrate that oral midazolam provides safe and effective sedation and anxiolysis prior to surgical procedures that require anesthesia as well as before other procedures that require sedation but may not require anesthesia. The most commonly reported effective doses range from 0.25 to 1 mg/kg in children (6 months to <16 years). The single most commonly reported effective dose is 0.5 mg/kg. Time to onset of effect is most frequently reported as 10 to 20 minutes.
The effects of midazolam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
2.0 nM [Ki] | |||
Target ID: CHEMBL1810 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2566295 |
3.2 µM [Ki] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10565838 |
183.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Midazolam Approved UseMidazolam hydrochloride syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia.
Midazolam hydrochloride syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS). MIDAZOLAM HYDROCHLORIDE SYRUP MUST BE USED AS SPECIFIED IN THE LABEL.
Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours Launch Date1985 |
|||
Primary | Midazolam Approved UseMidazolam HCl syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. Midazolam HCl syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS). MIDAZOLAM HCl SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours Launch Date1985 |
|||
Primary | Midafresa Approved UseEpilepsy Launch Date2014 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
54.7 ng/mL |
5 mg single, nasal dose: 5 mg route of administration: Nasal experiment type: SINGLE co-administered: |
MIDAZOLAM unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
113.9 ng/mL |
10 mg single, intramuscular dose: 10 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
MIDAZOLAM unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
35.124 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01989169 |
6 mg single, oral dose: 6 mg route of administration: oral experiment type: single co-administered: |
MIDAZOLAM plasma | Homo sapiens population: healthy age: Adults sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
126.2 ng × h/mL |
5 mg single, nasal dose: 5 mg route of administration: Nasal experiment type: SINGLE co-administered: |
MIDAZOLAM unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
402.7 ng × h/mL |
10 mg single, intramuscular dose: 10 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
MIDAZOLAM unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
100.935 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01989169 |
6 mg single, oral dose: 6 mg route of administration: oral experiment type: single co-administered: |
MIDAZOLAM plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
103.348 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01989169 |
6 mg single, oral dose: 6 mg route of administration: oral experiment type: single co-administered: |
MIDAZOLAM plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
30 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217 |
2 mg single, oral dose: 2 mg route of administration: oral experiment type: single co-administered: |
MIDAZOLAM plasma | Homo sapiens population: healthy age: adults sex: food status: |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3% |
5 mg single, nasal dose: 5 mg route of administration: Nasal experiment type: SINGLE co-administered: |
MIDAZOLAM unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3% |
10 mg single, intramuscular dose: 10 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
MIDAZOLAM unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 mg single, intranasal MTD Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Co-administed with:: sufentanil(0.4 mg/kg) Sources: |
unknown, 18 - 65 years n = 30 Health Status: unknown Condition: gastroscopy Age Group: 18 - 65 years Sex: unknown Population Size: 30 Sources: |
Other AEs: Nausea, Hypotension... |
5 mg 1 times / month multiple, intranasal (mean) Recommended Dose: 5 mg, 1 times / month Route: intranasal Route: multiple Dose: 5 mg, 1 times / month Sources: |
unhealthy, > 12 years n = 161 Health Status: unhealthy Condition: seizure clusters Age Group: > 12 years Sex: unknown Population Size: 161 Sources: |
Disc. AE: Nasal discomfort, Somnolence... Other AEs: Nasal discomfort, Somnolence... AEs leading to discontinuation/dose reduction: Nasal discomfort (1 patient) Other AEs:Somnolence (1 patient) Nasal discomfort (12.4%) Sources: Somnolence (9.3%) |
5 mg single, intranasal (mean) Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unknown, adult and children n = 87740 Health Status: unknown Condition: gastroscopy Age Group: adult and children Sex: M+F Population Size: 87740 Sources: |
Other AEs: Hypoxemia, Hypotension... Other AEs: Hypoxemia (90 patients) Sources: Hypotension (5 patients) |
5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Other AEs: Somnolence, Headache... Other AEs: Somnolence (10%) Sources: Headache (7%) Dysarthria (2%) Nasal discomfort (5%) Throat irritation (2%) Rhinorrhea (3%) Lacrimation increased (1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypotension | 5 mg single, intranasal MTD Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Co-administed with:: sufentanil(0.4 mg/kg) Sources: |
unknown, 18 - 65 years n = 30 Health Status: unknown Condition: gastroscopy Age Group: 18 - 65 years Sex: unknown Population Size: 30 Sources: |
|
Nausea | 5 mg single, intranasal MTD Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Co-administed with:: sufentanil(0.4 mg/kg) Sources: |
unknown, 18 - 65 years n = 30 Health Status: unknown Condition: gastroscopy Age Group: 18 - 65 years Sex: unknown Population Size: 30 Sources: |
|
Nasal discomfort | 1 patient Disc. AE |
5 mg 1 times / month multiple, intranasal (mean) Recommended Dose: 5 mg, 1 times / month Route: intranasal Route: multiple Dose: 5 mg, 1 times / month Sources: |
unhealthy, > 12 years n = 161 Health Status: unhealthy Condition: seizure clusters Age Group: > 12 years Sex: unknown Population Size: 161 Sources: |
Somnolence | 1 patient Disc. AE |
5 mg 1 times / month multiple, intranasal (mean) Recommended Dose: 5 mg, 1 times / month Route: intranasal Route: multiple Dose: 5 mg, 1 times / month Sources: |
unhealthy, > 12 years n = 161 Health Status: unhealthy Condition: seizure clusters Age Group: > 12 years Sex: unknown Population Size: 161 Sources: |
Nasal discomfort | 12.4% | 5 mg 1 times / month multiple, intranasal (mean) Recommended Dose: 5 mg, 1 times / month Route: intranasal Route: multiple Dose: 5 mg, 1 times / month Sources: |
unhealthy, > 12 years n = 161 Health Status: unhealthy Condition: seizure clusters Age Group: > 12 years Sex: unknown Population Size: 161 Sources: |
Somnolence | 9.3% | 5 mg 1 times / month multiple, intranasal (mean) Recommended Dose: 5 mg, 1 times / month Route: intranasal Route: multiple Dose: 5 mg, 1 times / month Sources: |
unhealthy, > 12 years n = 161 Health Status: unhealthy Condition: seizure clusters Age Group: > 12 years Sex: unknown Population Size: 161 Sources: |
Hypotension | 5 patients | 5 mg single, intranasal (mean) Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unknown, adult and children n = 87740 Health Status: unknown Condition: gastroscopy Age Group: adult and children Sex: M+F Population Size: 87740 Sources: |
Hypoxemia | 90 patients | 5 mg single, intranasal (mean) Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unknown, adult and children n = 87740 Health Status: unknown Condition: gastroscopy Age Group: adult and children Sex: M+F Population Size: 87740 Sources: |
Lacrimation increased | 1% | 5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Somnolence | 10% | 5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Dysarthria | 2% | 5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Throat irritation | 2% | 5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Rhinorrhea | 3% | 5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Nasal discomfort | 5% | 5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Headache | 7% | 5 mg single, intranasal Recommended Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: intermittent, stereotypic episodes of frequent seizure activity Age Group: adult Sex: unknown Population Size: 91 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Ki 3.7 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15544435/ Page: 9.0 |
yes [Ki 5.8 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211321Orig1s000ClinPharmR.pdf#page=11 Page: 11,12 |
major | yes (co-administration study) Comment: INHIBITORS: Coadministration with cimetidine: AUC increase of MDZ=10-102%; diltiazem: AUC increase of MDZ=275%; erythromycin: AUC increase of MDZ=281-341; fluconazole: AUC increase of MDZ=250%; grapefruit juice: AUC increase of 52%; itraconazole: AUC increase of MDZ=240-980%; ketoconazole: AUC increase of MDZ=1490%; ranitidine: AUC increase of MDZ=9-66%. INDUCERS: coadministration with carbamazepine: AUC decrease of MDZ=94%; phenytoin: AUC decrease of MDZ=94%; rifampin: AUC decrease of MDZ=96%; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211321Orig1s000ClinPharmR.pdf#page=11 Page: 11,12 |
||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18256203/ Page: 8.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation. | 1999 Dec |
|
Anticonvulsants for soman-induced seizure activity. | 1999 Mar-Apr |
|
Flumazenil antagonizes midazolam-induced airway narrowing during nasal breathing in humans. | 1999 May |
|
A double-blind placebo controlled trial of oral midazolam as premedication before flexible sigmoidoscopy. | 1999 Nov |
|
No reduction in the sufentanil requirement of elderly patients undergoing ventilatory support in the medical intensive care unit. | 1999 Oct |
|
Myoclonic movements in very low birth weight premature infants associated with midazolam intravenous bolus administration. | 1999 Sep |
|
Mice lacking the long splice variant of the gamma 2 subunit of the GABA(A) receptor are more sensitive to benzodiazepines. | 2000 Jun |
|
Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by gamma-aminobutyric acid(A) receptors in hippocampal neurons. | 2001 Apr |
|
Preparation, premedication, and surveillance. | 2001 Feb |
|
[Epileptogenic drugs in anesthesia]. | 2001 Feb |
|
Propofol as a continuous infusion during cardiopulmonary bypass does not affect changes in serum free fatty acids. | 2001 Feb |
|
Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison. | 2001 Feb |
|
The use of thiopentone/propofol admixture for laryngeal mask airway insertion. | 2001 Feb |
|
Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo. | 2001 Feb |
|
The use of esmolol as an alternative to remifentanil during desflurane anesthesia for fast-track outpatient gynecologic laparoscopic surgery. | 2001 Feb |
|
In situ nasal absorption of midazolam in rats. | 2001 Feb 1 |
|
[Premedication in ambulatory surgery]. | 2001 Feb 12 |
|
[Premedication for endoscopy]. | 2001 Feb 2 |
|
Intra-nasal midazolam in conscious sedation of young paediatric dental patients. | 2001 Jan |
|
Ketamine-midazolam total intravenous anaesthesia for prolonged abdominal surgery. | 2001 Jan |
|
[Anesthetic experience of emergency coronary artery bypass graft operation in a patient with cardioamyloidosis]. | 2001 Jan |
|
[Anesthetic management for mitral valve replacement in a patient with idiopathic hypereosinophilic syndrome]. | 2001 Jan |
|
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice. | 2001 Jan |
|
Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam. | 2001 Jan |
|
S(+)-ketamine for rectal premedication in children. | 2001 Jan |
|
A comparison of oral clonidine and oral midazolam as preanesthetic medications in the pediatric tonsillectomy patient. | 2001 Jan |
|
Intranasal midazolam for treating febrile seizures in children. Buccal midazolam for childhood seizures at home preferred to rectal diazepam. | 2001 Jan 13 |
|
Intranasal midazolam for treating febrile seizures in children. Safety is as important as efficacy. | 2001 Jan 13 |
|
Intranasal midazolam for treating febrile seizures in children. Caution is required in applying hospital based evidence to primary care population. | 2001 Jan 13 |
|
Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam. | 2001 Jan 13 |
|
A retrospective study on the effectiveness of intranasal midazolam in pediatric burn patients. | 2001 Jan-Feb |
|
Synergistic analgesic effects of intrathecal midazolam and NMDA or AMPA receptor antagonists in rats. | 2001 Mar |
|
Selective spinal anesthesia for outpatient laparoscopy. II: epinephrine and spinal cord function. | 2001 Mar |
|
Drugs and syringe drivers: a survey of adult specialist palliative care practice in the United Kingdom and Eire. | 2001 Mar |
|
Anaesthetic technique for transoesophageal echocardiography in children. | 2001 Mar |
|
The effect of anxiety and personality on the pharmacokinetics of oral midazolam. | 2001 Mar |
|
Management of background pain and anxiety in critically burned children requiring protracted mechanical ventilation. | 2001 Mar-Apr |
|
Burn patients' pain and anxiety experiences. | 2001 Mar-Apr |
|
Onset and duration of action of rocuronium--from tracheal intubation, through intense block to complete recovery. | 2001 May |
|
Characterization of discriminative stimulus effects of the neuroactive steroid pregnanolone. | 2001 May |
|
Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. | 2001 May |
Patents
Sample Use Guides
Midazolam hydrochloride syrup is indicated for use as a single dose (0.25 to 1 mg/kg with a maximum dose of 20 mg) for preprocedural sedation and anxiolysis in pediatric patients. Midazolam hydrochloride syrup is not intended for chronic administration.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8173965
Midazolam (1 uM) decreased GABA-activated currents in acutely dissociated neurons, isolated from the medial septum/nucleus of the diagonal band (MS/nDB) of the adult rat brains.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:48:03 GMT 2023
by
admin
on
Fri Dec 15 15:48:03 GMT 2023
|
Record UNII |
R60L0SM5BC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2884
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
WHO-VATC |
QN05CD08
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
514115
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
LIVERTOX |
NBK548691
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
373912
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
1.3
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
622817
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
507615
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
217405
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
WHO-ATC |
N05CD08
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
NDF-RT |
N0000175694
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
508215
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
277809
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5023320
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
6960
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | RxNorm | ||
|
1443599
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
4497
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
MIDAZOLAM
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
6932
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
R60L0SM5BC
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
C62049
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
D008874
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
SUB08950MIG
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
59467-70-8
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
Midazolam
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
261-774-5
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
DB00683
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
m7531
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
3342
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
6931
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
4192
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL655
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
7581
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
6751
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
100000080626
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
R60L0SM5BC
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY | |||
|
1802
Created by
admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||